Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE SODIUM PHOSPHATE versus CORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE SODIUM PHOSPHATE versus CORTISONE ACETATE.
BETAMETHASONE SODIUM PHOSPHATE vs CORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to suppress inflammation, immune response, and reduce capillary permeability.
Corticosteroid with glucocorticoid and mineralocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses.
0.5-9 mg/day IV or IM in divided doses every 12-24 hours; acute conditions may require 4-8 mg IV initially.
25-300 mg per day orally, in divided doses every 6-12 hours, depending on condition severity.
None Documented
None Documented
Terminal elimination half-life: 5-6 hours (plasma); biological half-life (HPA axis suppression): 24-36 hours.
Clinical Note
moderateCortisone acetate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Gatifloxacin."
Clinical Note
moderateCortisone acetate + Rosoxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rosoxacin."
Clinical Note
moderateCortisone acetate + Levofloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Levofloxacin."
Clinical Note
moderate30 minutes (plasma half-life of cortisol); biological half-life 8-12 hours (due to intracellular receptor binding and transcriptional effects)
Renal: 90-95% as inactive metabolites; biliary/fecal: <5%.
Renal (approximately 90% as metabolites, <5% unchanged); biliary/fecal (<5%)
Category D/X
Category C
Corticosteroid
Corticosteroid
Cortisone acetate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Trovafloxacin."